Bioequivalence study of mefenamic acid capsule 250 mg

计划入组 24 人

A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo

计划入组 100 人 · 首次发布于 2015 年 12 月 31 日

Phase I Human Analytics (HALO) Study

计划入组 2,000 人 · 首次发布于 2022 年 6 月 21 日

RNAi Therapeutics(Halo-Bio RNAi Therapeutics, Inc.)

Thalidomide inhalation (Vicore Pharma)

Ezetimibe/obicetrapib (NewAmsterdam Pharma)

Halo Pharmaceutical, Inc.

United States

Halo Pharmaceutical Canada, Inc.

Canada

Halo Pharmaceutical Canada Inc

Canada

Halo Pharma Emerges as Independent CDMO Following Noramco Group Divestiture to Siegfried

Noramco Group Invests $25 Million to Establish Sterile Injectable Manufacturing in New Jersey

Ascelia Pharma Nears Orviglance NDA Submission for Orphan Liver Imaging Agent